We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FDA Advises Sponsors of New Drugs, Biologics on Assessing Immunotoxicity
FDA Advises Sponsors of New Drugs, Biologics on Assessing Immunotoxicity
The FDA details how sponsors of nonclinical safety evaluations of new drugs and therapeutic proteins should consider their impact on the immune system, in a draft guidance released yesterday.